This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.0 | Synonyms: Familial hypoplastic anemia, Inherited hypoplastic anemia, Familial bone marrow hypoplasia
Familial hypoplastic anemia is a heterogeneous group of disorders characterized by bone marrow hypoplasia and pancytopenia recurring within the same family. The concept was gradually subdivided in the 1930s–1950s as separate clinical entities showing familial occurrence were described, such as Fanconi anemia (1927), Diamond-Blackfan syndrome (1938) and Shwachman-Diamond syndrome (1964). Initially, these syndromes were discussed within a single 'familial aplastic anemia' spectrum.
Since the 1990s, advances in molecular genetics have revealed the specific causative genes of each syndrome, allowing familial hypoplastic anemia to be defined more precisely. The FANC gene family (1992–present), SBDS (2003), RPS19 and other ribosomal protein genes (2000s), GATA2 (2011) and others were discovered in turn.
Today, familial hypoplastic anemia is used as a descriptive concept encompassing all inherited bone marrow failure syndromes rather than as an independent diagnostic category, and within ICD-10 code D61.0 it is classified together with Fanconi anemia, Blackfan-Diamond syndrome and others. Familial cases whose cause has not been clearly identified still exist within this category.
Familial hypoplastic anemia is a very heterogeneous group of disorders in terms of causative genes. Known causes include defects in DNA damage repair genes (FANC gene family), defects in ribosome biogenesis genes (RPS/RPL gene family), defects in telomere maintenance genes (TERC, TERT, DKC1, etc.), transcription factor abnormalities (GATA2), and a gene for ribosome biogenesis and exocrine pancreatic function (SBDS).
There are cases in which no variants are found in currently known genes despite recurrent occurrence within a family. This suggests that new causative genes not yet discovered exist, or that variants in noncoding regions or epigenetic abnormalities may be involved.
In some individuals with a genetic predisposition, environmental factors (infection, toxins, radiation exposure) may act as triggers for disease onset. Even among siblings with the same genetic background, there are differences in age of onset and severity, suggesting that interaction with environmental factors affects disease expression.
Various modes of inheritance are observed depending on the syndrome causing familial hypoplastic anemia. They include autosomal recessive (Fanconi anemia, Shwachman-Diamond syndrome, some forms of dyskeratosis congenita), autosomal dominant (most cases of Diamond-Blackfan syndrome, TERC-related dyskeratosis congenita, GATA2 deficiency) and X-linked recessive (DKC1-related dyskeratosis congenita).
Even within families carrying the same gene variant, the phenotype may vary (variable expressivity). Mild hematologic abnormalities may also be observed in some carriers, which should be considered in genetic counseling. Because of incomplete penetrance, there may be family members who carry the variant without symptoms.
Rarely, cases have been reported in which heterozygous variants are present simultaneously in two or more genes associated with inherited bone marrow failure, causing disease through complex inheritance. Elucidating such complex inheritance patterns requires whole-exome or whole-genome sequencing.
The exact incidence of familial hypoplastic anemia as a whole is difficult to determine, but when all inherited bone marrow failure syndromes are included it is estimated at 5–15 per million births. The incidence of specific syndromes is reported individually, e.g., Fanconi anemia about 1–3 per million births and Diamond-Blackfan syndrome about 5–10 per million births.
In Korea, patients with congenital bone marrow failure syndromes, including familial hypoplastic anemia, receive care at major pediatric hematology-oncology centers nationwide. According to data from the Korean Society for Rare Diseases and the Health Insurance Review & Assessment Service (HIRA), patients in this category receive the Special Copayment Reduction for rare diseases, and domestic studies have reported part of the Korean-specific gene variant spectrum.
Fanconi anemia occurs at particularly high frequency in Ashkenazi Jews (FANCC IVS4+4 A>T variant) and the Afrikaner population of South Africa (FANCA founder mutation). In most other ethnic groups it occurs sporadically.
In familial hypoplastic anemia, reduced self-renewal capacity or progressive exhaustion of hematopoietic stem cells is the core pathogenesis. Depending on the genetic defect, failure of DNA repair, hyperactivation of apoptosis, impaired ribosome biogenesis, accelerated telomere shortening and others act in combination to reduce the number of functional hematopoietic stem cells.
Hyperactivation of the p53 pathway is commonly observed in several inherited bone marrow failure syndromes. Different upstream stimuli, such as DNA damage (Fanconi anemia), ribosomal stress (Diamond-Blackfan) and telomere dysfunction (dyskeratosis congenita), ultimately converge on p53 stabilization → cell cycle arrest and increased apoptosis.
In some forms of familial hypoplastic anemia, dysfunction of bone marrow stromal cells (stromal cells, endothelial cells) reduces their hematopoietic stem cell support function. In GATA2 deficiency, endothelial cell abnormalities are known to be associated with reduced secretion of hematopoiesis-supporting cytokines such as CXCL12.
The clinical symptoms of familial hypoplastic anemia consist of three main symptom groups: anemia (fatigue, pallor, dyspnea), thrombocytopenia (bleeding tendency, purpura, nosebleeds) and neutropenia (recurrent infections, fever). The age of symptom onset and severity vary depending on the causative syndrome and gene variant.
In Fanconi anemia, various congenital anomalies (skin pigmentation abnormalities, thumb and radial anomalies, renal anomalies, cardiac anomalies, microcephaly, etc.) may appear before hematologic symptoms. Shwachman-Diamond syndrome is accompanied by exocrine pancreatic insufficiency (steatorrhea, growth failure). In dyskeratosis congenita, three mucocutaneous findings are characteristic: nail dysplasia, reticular skin pigmentation and oral leukoplakia.
Many congenital hypoplastic anemia syndromes are accompanied by growth failure and endocrine abnormalities (hypogonadism, hypothyroidism, diabetes), which result from the bone marrow failure itself or from treatment complications (transfusion-related iron overload, transplant-related conditioning).
Pallor, cutaneous petechiae and purpura, and mucosal bleeding are common signs. The presence of congenital anomalies (finger abnormalities, skin pigmentation abnormalities, short stature) is an important clue suggesting a familial/congenital form. Splenomegaly is absent or mild, and with infection, fever and signs of infection are observed.
Pancytopenia (complete blood count), macrocytic red cells (increased MCV) and elevated fetal hemoglobin (HbF) are characteristic. Bone marrow biopsy shows reduced cellularity (<25%) and fatty replacement. Serum EPO is markedly elevated relative to the degree of anemia.
Syndrome-specific test findings are used for diagnosis, such as the DEB/MMC chromosomal breakage test (Fanconi anemia), telomere length measurement (dyskeratosis congenita), flow cytometry (abnormal lymphocyte subsets in GATA2 deficiency), and serum amylase/lipase and fecal elastase (Shwachman-Diamond).
Familial hypoplastic anemia should be suspected when recurrent anemia or cytopenias are reported within a family. In children, an unexplained combination of pancytopenia and congenital anomalies is the strongest screening clue.
Complete blood count, reticulocyte count, serum EPO, liver function tests and fetal hemoglobin measurement are used for initial screening. In children, elevated MCV and HbF are important indicators suggesting a congenital form.
Next-generation sequencing (NGS)-based multigene panel testing for inherited bone marrow failure syndromes is used as the standard method for identifying the cause in suspected patients. In addition, in certain ethnic groups (Ashkenazi Jews, etc.), screening for common founder mutations may be performed first.
Familial hypoplastic anemia is diagnosed by a stepwise approach: confirmation of pancytopenia, confirmation of bone marrow hypoplasia, exclusion of acquired causes, assessment of family history and congenital anomalies, syndrome-specific testing, and identification of the causative gene.
Fanconi anemia: DEB/MMC chromosomal breakage test, followed by a FANC gene panel if confirmed; Diamond-Blackfan syndrome: erythroblast deficiency and ribosomal protein gene variants; dyskeratosis congenita: telomere length (flow cytometry, FISH) and telomere gene variants; Shwachman-Diamond: SBDS gene variants, exocrine pancreatic function tests; GATA2 deficiency: GATA2 gene variants, abnormal lymphocyte subsets (reduced NK and B cells).
Differentiation is needed from acquired aplastic anemia (response to immunosuppressive therapy), PNH, myelodysplastic syndrome, nutritional deficiencies (vitamin B12, folate) and bone marrow suppression due to infection (Parvovirus B19, EBV, CMV).
Allogeneic hematopoietic stem cell transplantation is the only curative treatment for familial hypoplastic anemia. Transplantation from an HLA-matched sibling donor is best; if none is available, an unrelated donor or haploidentical transplant is considered. The intensity of conditioning must be adjusted according to whether each syndrome has a DNA repair defect.
Androgens (danazol, oxymetholone) stimulate hematopoiesis and improve blood counts in some patients. G-CSF is used for neutropenia, but the possibility of promoting secondary tumors with long-term use is considered. Eltrombopag (a thrombopoietin receptor agonist) is being tried in some inherited bone marrow failure disorders to improve platelets and other blood cell lineages.
Regular transfusions (red blood cells, platelets), infection prevention (antibiotics, antifungals, antivirals), iron chelation therapy (in chronically transfused patients) and nutritional supplementation (including pancreatic enzyme replacement in Shwachman-Diamond) are the foundation of supportive treatment.
The prognosis of familial hypoplastic anemia varies greatly depending on the type of causative syndrome, severity, feasibility of transplantation and occurrence of secondary tumors. When appropriate hematopoietic stem cell transplantation is performed, the 5-year survival rate can reach 70–90%. When managed with transfusions alone without transplantation, the long-term prognosis is poor and the risk of secondary tumors is high.
In many congenital hypoplastic anemia syndromes, the risk of secondary malignancies—AML/MDS and solid tumors—is significantly increased. Even after successful transplantation, the risk of secondary solid tumors persists, requiring lifelong surveillance.
Endocrine complications (growth failure, hypogonadism, hypothyroidism), reduced bone density, neurocognitive developmental abnormalities and transplant-related complications (graft-versus-host disease, infertility) affect quality of life. Management of long-term complications through a multidisciplinary approach is important.
Genetic counseling and screening are offered to all family members of patients with confirmed familial hypoplastic anemia. Heterozygous carrier parents are offered prenatal diagnostic options (CVS, amniocentesis, PGT-M) for subsequent pregnancies.
The development of secondary tumors is prevented as much as possible by minimizing exposure to carcinogenic environmental factors, avoiding tobacco and alcohol, HPV vaccination, regular endoscopic surveillance, regular dermatologic examinations and so on. Alkylating agents and irradiation are avoided or minimized as much as possible.
Through a systematic multidisciplinary follow-up program covering bone marrow function, secondary tumors, endocrine function, growth, neurocognitive development and more, complications are detected early and preventive interventions are carried out.